You're right on the money Bruce. Another consideration of
You're right on the money Bruce. Another consideration of R&D being down in the quarter could be completion of the efficacy trial, and while they're planning other trials, the real expenses don't begin until they're underway, which may not be this year if the trials are to be FDA approved.
I suspect that much of their future work will be done by Sheba, but as trials get larger I would also suspect that they'll bring in other clinical sites, and that may cost money.
As you probably know, I'm a patient at City of Hope. I know that they have developed some of the most successful drugs on the market today, and they receive some royalty money for doing so. I also believe they're willing to do trials with anything they believe can benefit their patients, but I'm uncertain if they charge, and if they do, I don't believe the charge is very high, as their Doctor's want to be working with cutting edge medicines.
My therapy has essentially been with approved drugs, and a stem cell transplant, but the chemo I'm on is not specifically approved for my form of leukemia. My Dr. considers it the third generation of Gleevec, and believes it superior, so that's what I'm on. I have met a few people there which City of Hope actually made personalized drugs for them which to date are saving their lives. They don't give up when all know products have failed.
Gary
3
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Top 5 Most Recently Viewed Articles
Welcome to New Beginnings in North Dakota As the season of relocation kicks off, North Dakota is inviting jobseekers with its innovative campaign, Find the Good Life in North Dakota. This initiative coincides with National Moving Day, marking the start of a bustling season when many families seek new horizons across the country. Embrace New Opportunities "People are on...
Continue Reading
Celebrating Industry Recognition Caseware™, a pioneer in AI-enabled audit, financial reporting, and data analytics, has recently basked in a wave of industry accolades. These recognitions underscore the company's unmatched leadership in driving innovation and delivering impactful solutions to accounting professionals worldwide. A Double Triumph for Caseware In a...
Continue Reading
Telomir Pharmaceuticals Sees Significant Pre-market Surge Shares of Telomir Pharmaceuticals Inc (NASDAQ: TELO) experienced a remarkable increase of 31%, reaching $1.86 in pre-market trading. This boost comes in the wake of encouraging preclinical results regarding their primary compound, Telomir-1. Promising Preclinical Study Results The biotechnology firm disclosed these...
Continue Reading
Market Overview for Potential Rebounds The stock market is often unpredictable, with certain stocks experiencing declines even after positive earnings reports. In recent times, some stocks have evidently fallen out of favor with investors, particularly following disappointing earnings or cautious guidance from companies. Interestingly, stocks with low expectations can...
Continue Reading
Acer Inc. Demonstrates Strong Quarter Over Quarter Growth Acer Inc. (TWSE: 2353) has recently shared impressive financial results for the third quarter of 2024, showcasing resilience and growth in a competitive market. The company reported consolidated revenues of NT$72.69 billion, reflecting an 8.3% increase compared to the previous quarter and a 7.8% rise year-on-year....
Continue Reading
